Prevention and management of cardiovascular disease in patients with diabetes mellitus: An evidence base

Diabetic Medicine

Volumn 13, Issue SUPPL. 4, 1996, Pages

  Yudkin, J S ^c,d   Blauth, C ^e   Drury, P ^h   Fuller, J ⁱ   Henley, J ^b   Lancaster, T ^j   Lankester, J ^f   Lean, M ^g   Pentecost, B ^k   Press, V ^a   Rothman, D ^b  

^a Department of Health ^*  (United Kingdom)

^b British Diabetic Association   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d WHITTINGTON HOSPITAL   (United Kingdom)

^e Cardiothoracic Unit

^f CAMDEN AND ISLINGTON NHS FOUNDATION TRUST   (United Kingdom)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

^h Uni Services House   (New Zealand)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j RADCLIFFE INFIRMARY   (United Kingdom)

^k KING'S COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; CALCIUM ANTAGONIST; CAPTOPRIL; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FATTY ACID; FIBRIC ACID DERIVATIVE; FIBRINOLYTIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT;

ATHEROSCLEROSIS; CARDIOGENIC SHOCK; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DILATATION; DIABETES MELLITUS; FITNESS; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; OBESITY; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; RISK FACTOR; SMOKING CESSATION; SODIUM RESTRICTION; STROKE;

EID: 9544230669     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. World Health Organization (Europe) and International Diabetes Federation (Europe). Diabetes care and research in Europe: the St Vincent Declaration. Diabetic Med 1990; 7: 360-370.
2. Department of Health. The Health of the Nation: A Strategy for Health in England. Cm 1986. London: HMSO, 1992.
3. Fuller JH, Shipley MJ, Rose G, et al. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall Study. Lancet 1980; i: 1373-1376.
4. Rosengren A, Welin L, Tsipogianni, et al. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study. Br Med J 1989; 299: 1127-1131.
5. Bell DSH. Stroke in the diabetic patient. Diabetes Care 1994; 17: 213-219.
6. Nesto RW, Phillips RT, Kett KG, et al. Angina and exertional myocardial ischemia in diabetic and nondiabetic patients: assessment by exercise thallium scintigraphy. Ann Intern Med 1988; 108: 170-175.
7. Scheidt-Nave C, Barrett-Connor E, Wingard DL. Resting electrocardiographic abnormalities suggestive of asymptomatic ischemic heart disease associated with non-insulin-dependent diabetes mellitus in a defined population. Circulation 1990; 81: 899-906.
8. Yudkin J, Hendra TJ. Vascular events and diabetes; acute myocardial infarction and stroke. In: Alberti KGMM, Keen HA and De Fronzo RA, eds. International Textbook of Diabetes Mellitus. Chichester: Wiley, 1992.
9. Pulsinelli WA, Levy DE, Sigsbee B, et al. Increased damage after ischemic stroke in patients with hyperglycemia with or without established diabetes mellitus. Am J Med 1983; 74: 540-544.
10. Weiner DA, Ryan TJ, Parsons L, et al. Significance of silent myocardial ischemia during exercise testing in patients with diabetes mellitus: a report from the Coronary Artery Surgery Study (CASS) Registry. Am J Cardiol 1991; 68: 729-734.
11. Kannel WB. Role of diabetes in cardiac disease: conclusions from population studies. In Zoneraich S, ed. Diabetes and the Heart. Springfield: Thomas, 1978: 97-112.
12. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991; 34: 877-890.
13. Morrish NJ, Stevens LK, Fuller JH, et al. Risk factors for macrovascular disease in diabetes mellitus: the London follow-up to the WHO Multinational Study of Vascular Disease in Diabetics. Diabetologia 1991; 34: 590-594.
14. Morrish NJ, Stevens LK, Fuller JH, et al. Incidence of macrovascular disease in diabetes mellitus: the London cohort of the WHO Multinational Study of Vascular Disease in Diabetics. Diabetologia 1991; 34: 584-589.
15. Morrish NJ, Stevens LK, Head J, et al. A prospective study of mortality among middle-aged diabetic patients (the London cohort of the WHO Multinational Study of Vascular Disease in Diabetics) II: associated risk factors. Diabetologia 1990; 33: 542-584.
16. Stephenson J, Swerdlow AJ, Devis T, et al. Recent trends in diabetes mortality in England and Wales. Diabetic Med 1992; 9: 417-421.
17. Robinson N, Edouard L, Diehl A, et al. Social class and risk factors for vascular disease in diabetes. Diabete Metabolisme 1984; 10: 245-249.
18. Ben-Schlomo Y, Chaturvedi N. Assessing equity in access to health care provision in the UK: does where you live affect your chances of getting a CABG? J Epidemiol Comm Hlth 1994; in press.
19. McKeigue PM, Shah B, Marmot MG. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet 1991; 337: 382-386.
20. Chaturvedi N, Fuller JH. Ethnic differences in mortality from cardiovascular disease in the UK: do they persist in people with diabetes? J Epidemiol Comm Hlth 1996; 50: in press.
21. Fontbonne N, Eschwege E, Cambien F, et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Diabetologia 1989; 32: 300-304.
22. Chaturvedi N, McKeigue PM, Marmot MG. Relationship of glucose intolerance to coronary risk in Afro-Caribbeans compared with Europeans. Diabetologia 1994; 37: 765-772.
23. Stamler J, Vaccaro O, Neaton JD, et al. for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.
24. Jarrett J. Mortality in Diabetes. Quart J Med 1990; 75: 413-414.
25. Laakso M, Lehto S, Pentillä I, et al. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993; 88: 1421-1430.
26. Stewart MW, Laker MF, Dyer RG, et al. Lipoprotein compositional abnormalities and insulin resistance in type II diabetic patients with mild hyperlipidemia. Arterioscler Thromb 1993; 13: 1046-1052.
27. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
28. Mühlhauser I. Cigarette smoking and diabetes: an update. Diabetic Med 1994; 11: 336-343.
29. Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med 1987; 294: 1651-1654.
30. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-360.
31. Baynes C, Henderson AD, Anyaoku V, et al. The influence of regional adiposity on atherogenic risk factors in men and women with type 2 diabetes. Diabetic Med 1991; 8: 458-463.
32. Wilhemsen L, Svärdsudd K, Korstan-Bengtsen K, et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505.
33. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; ii: 3-9.
34. Nagi DK, Hendra TJ, Ryle AJ, et al. The relationship of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin dependent) diabetic subjects. Diabetologia 1990; 33: 532-537.
35. Oswald G, Smith C, Betteridge DJ, et al. Determinants and importance of stress hyperglycaemia in non diabetic patients with myocardial infarction. Br Med J 1986; 293: 917-922.
36. Malmberg K, Rydén L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
37. Damsgaard EM, Froland A, Green A. Use of hospital services by elderly diabetics: The Fredericia study of diabetic and fasting hyperglycaemic patients aged 60-74 years. Diabetic Med 1987; 4: 317-322.
38. Dornan TL, Peck GM, Dow JDC, et al. A community survey of diabetes in the elderly. Diabetic Med 1992; 9: 860-865.
39. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J 1994; 308: 367-372.
40. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
41. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
42. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995; 333: 1301-1307.
43. Yudkin JS. How can we best prolong life? The benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. Br Med J 1993; 306: 1313-1318.
44. Pyörälä K, Pedersen TR, Kjekshus J. The effect of cholesterol lowering with Simvastatin on coronary events in diabetic patients with coronary heart disease (Abstract). Diabetes 1995; 44: 35A.
45. Davey Smith G, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. Br Med J 1993; 306: 1367-1373.
46. Antiplatelet Trialists' Collaboration. Collaborative overiew of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
47. Jackson R, Barham P, Bills J, et al. Management of raised blood pressure in New Zealand: a discussion document. Br Med J 1993; 307: 107-110.
48. Yudkin JS. Which diabetic patients should be taking aspirin? Br Med J 1995; 311: 641-642.
49. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J 1982; 285: 685-688.
50. Parving H-H, Andersen AR, Smidt UM, et al. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; 1: 1175-1179.
51. Mathiesen ER, Borch-Johnsen K, Jensen DV, et al. Improved survival in patients with diabetic nephropathy. Diabetologia 1989; 32: 884-886.
52. Keen H (Chairman). Blood Pressure and Diabetes - Everyone's Concern. British Diabetic Association Working Party, Draft Report. Feb 1994. London: RR Associates.
53. Sever P, Beevers G, Bulpitt C, et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. Br Med J 1993; 306: 983-987.
54. The Fifth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Bethesda, MD: National Institutes of Health, National Heart, Lung and Blood Institute, 1993.
55. American Diabetes' Association Consensus Report. Treatment of Hypertension in Diabetes. Diabetes Care 1993; 16: 1394-1401.
56. Björck S, Nyberg G, Mulec H, et al. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 1986; 293: 471-474.
57. Parving H-H, Andersen AR, Smidt UM, et al. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J 1987; 294: 1443-1447.
58. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
59. Dodson PM, Beevers M, Hallworth R, et al. Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. Br Med J 1989; 298: 227-230.
60. Gey KF, Puska P, Jordan P, Moser UK. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr 1991; 53: 326S-334S.
61. Riemersma RA, Wood DA, Maclntyre CCA, et al. Risk of angina pectoris and plasma concentrations of vitamins A, C, and E and carotene. Lancet 1991; 337: 1-5.
62. Uusitupa MIJ, Niskanen LK, Siitonen O, et al. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in Type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 1993; 36: 1175-1184.
63. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
64. Walden CE, Knopp RH, Wahl PW, et al. Sex differences in the effect of diabetes mellitus on lipoprotein triglyceride and cholesterol concentrations. N Engl J Med 1984; 311: 953-995.
65. Bitzen P-O, Melander A, Schersten B, Svenson M. Efficacy of dietary regulation in primary health care patients with hyperglycaemia detected by screening. Diabetic Med 1988; 5: 640-647.
66. Bauman WA, Schwartz E, Rose HG, et al. Early and long-term effects of acute caloric deprivation in obese diabetic patients. Am J Med 1988; 85: 38-46.
67. Lean MEJ, Powrie JK, Anderson AS, et al. Obesity, weight loss and prognosis in type 2 diabetes. Diabetic Med 1990; 7: 228-233.
68. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? Lancet 1990; 336: 129-133.
69. Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine. In the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992; 339: 563-569.
70. Mensink RP, Katan MB. Effect of dietary trans fatty acids on high-density and low-density lipoprotein cholesterol levels in health subjects. N Engl J Med 1990; 323: 439-454.
71. Garg A, Bonanome A, Grundy SM, et al. Comparison of a high-carbohydrate diet with a high-monosaturated-fat diet in patients with diabetes mellitis. N Engl J Med 1988; 319: 829-834.
72. Shepherd J, Packard CJ, Grundy SM, et al. Effects of saturated and polyunsaturated fat diets on the chemical composition and metabolism of low density lipoproteins in man. J Lipid Res 1980; 21: 91-99.
73. Heine RJ. Dietary fish oil and insulin action in humans. Ann NY Acad Sci 1993; 683: 110-121.
74. Hopkins PN. Effects of dietary cholesterol on serum cholesterol: a meta-analysis and review. Am J Clin Nutr 1992; 55: 1060-1070.
75. Vinik AI, Jenkins DJA. Dietary fibre in the management of diabetes. Diabetes Care 1988; 11: 160-173.
76. Simpson HCR, Simpson RW, Lousley S, et al. A high carbohydrate leguminous fibre diet improves all aspects of diabetic control. Lancet 1981; i: 1-5.
77. Warshakfsky S, Kamer RS, Sivak SL. Effect of garlic on total serum cholesterol. Ann Intern Med 1993; 119: 599-605.
78. Nutrition Subcommittee; British Diabetic Association. Dietary recommendations for diabetics for the 1980s. Hum Nutr: Appl Nutr 1982; 36A: 378-394.
79. Close EJ, Wiles PG, Lockton JA, et al. Diabetic diets and nutritional recommendations: What happens in real life? Diabetic Med 1992; 9: 181-188.
80. McCulloch DK, Mitchell RD, Ambler J, et al. Influence of imaginative teaching of diet on compliance and metabolic control in insulin dependent diabetes. Br Med J 1983; 287: 1858-1861.
81. Lockwood D, Frey ML, et al. The biggest problem in diabetes. The Diabetes Educator 1986; 12: 30-33.
82. Christensen NK, Terry RD, Wyatt S, et al. Quantitative assessment of dietary adherence in patients with insulin-dependent diabetes mellitus. Diabetes Care 1983; 6: 245-255.
83. Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6 year Malmo feasibility study. Diabetologia 1990; 34: 891-898.
84. Burr ML, Gilbert JF, Holliday RM, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (Dart). Lancet 1989; 3: 757-761.
85. Dietary recommendations for people with diabetes: an update for the 1990s. Nutrition Subcommittee of the British Diabetic Association's Professional Advisory Committee. Diabetic Med 1992; 9: 189-202.
86. Armstrong J, Lean MEJ. The plate model for dietary education. Proc Nutr Soc 1993; 52: 19a.
87. The Carter Center of Emory University. Closing the gap: the problems of diabetes mellitus in the United States. Diabetes Care 1985; 8: 391-406.
88. Zuanetti G, Latini R, Maggioni AP, et al on behalf of GISSI-2 Investigators. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 Study. J Am Coll Cardiol 1993; 22: 1788-1794.
89. Gray RP, Yudkin JS, Patterson DL. Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: A role for plasminogen activator inhibitor? Br Heart J 1993; 70: 530-536.
90. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-322.
91. Ward H, Yudkin JS. Thrombolysis in patients with diabetes. Br Med J 1995; 310: 3-4.
92. Mahaffey KW, Granger CB, Stebbins AL, Califf RM for the GUSTO-1 Investigators. Diabetic retinopathy should not be a contraindication to thrombolytic therapy: quantification of risk in 6011 patients (Abstract). Circulation 1995; 92: (suppl 1): 1417.
93. Malmberg K, Herlitz J, Hjalmarson Å, et al. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies. Eur Heart J 1989; 10: 423-482.
94. Struthers AD. Ten years of natriuretic peptide research: a new dawn for their diagnostic and therapeutic use? Br Med J 1994; 308: 1615-1619.
95. Hubbard BL, Gibbons RJ, Lapeyre AC III, et al. Identification of severe coronary artery disease using simple clinical parameters. Arch Intern Med 1992; 152: 309-312.
96. Kanojia A, Kasliwal R, Seth A, et al. Clinical and coronary arteriographic features and outcome of recent onset unstable angina. Int J Cardiol 1993; 39: 173-180.
97. Bhan A, Das B, Wasir HS, et al. Profile of coronary arterial disease in diabetic patients undergoing coronary arterial bypass grafting. Int J Cardiol 1991; 31: 155-159.
98. Devineni R, McKenzie FN. Surgery for coronary artery disease in patients with diabetes mellitus. Can J Surg 1985; 28: 367-370.
99. Alderman EL, Corley SD, Fisher LD, et al. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol 1993; 22: 1141-1154.
100. Lawrie GM, Morris GC Jr, Glaeser DH. Influence of diabetes mellitus on the results of coronary bypass surgery. Follow-up ot 212 diabetic patients, ten to 15 years after surgery. J Am Med Assoc 1986; 256: 2967-2971.
101. Rahimtoola SH, Bennett AJ, Grunkemeier GL, et al. Survival at 15-18 years after coronary bypass surgery for angina in women. Circulation 1993; 88: 71-78.
102. Accola KD, Jones EL, Craver JM, et al. Bilateral mammary artery grafting: avoidance of complications with extended use. Ann Thorac Surgery 1993; 56: 872-879.
103. Morris JJ, Smith LR, Jones RH, et al. Influence of diabetes and mammary artery grafting on survival after coronary bypass. Circulation 1991; 84 (suppl III): 275-284.
104. Rensing BJ, Hermans WRM, Vos J, et al. Luminal narrowing after percutaneous transluminal coronary angioplasty: a study of clinical, procedural, and lesional factors related to long-term angiographic outcome. Circulation 1993; 88: 975-985.
105. Corruzza JP Jr, Kuntz RE, Fisherman RF, et al. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1993; 118: 344-349.
106. Hearn JA, King SB III, Douglas JS et al. Clinical and angiographic outcomes after coronary artery stenting for acute or threatened closure after percutaneous transluminal coronary angioplasty. Initial results with a balloon-expandable, stainless steel design. Circulation 1993; 88: 2086-2096.
107. White HD. Angioplasty versus bypass surgery. Lancet 1995; 346: 1174-1176.
108. Anon. CABG rather than PTCA for subset of diabetics. Lancet 1995; 346: 896.
109. Manske CL, Wang Y, Rector T, et al. Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure. Lancet 1992; 340: 998-1002.
110. Munoz E, Lonquist JL, Radovancevic B, et al. Long term results in diabetic patients undergoing heart transplantation. J Heart Lung Transplant 1992; 11: 943-949.
111. Guidelines for encouraging psychological wellbeing: Report of a working party of the World Health Organisation Regional Office for Europe and International Diabetes Federation European Region. St. Vincent Declaration Action Programme for Diabetes. Diabetic Med 1994; 11: 510-516.
112. Burnett SD, Woolf CM and Yudkin JS. Developing a district diabetic register. Br Med J 1992; 305: 627-630.
113. Williams DR, Fuller JH, Stevens LK. Validity of routinely collected hospital admissions data on diabetes. Diabetic Med 1989; 6: 320-324.
114. Fuller JH, Elford J, Goldblatt P, et al. Diabetes mortality: new light on an underestimated public health problem. Diabetologia 1983; 24: 336-341.
115. Vaughan NJA, Home PD for the Diabetes Audit Working Group of the Research Unit of the Royal College of Physicians and the British Diabetic Association. The UK Diabetes Dataset: a standard for information exchange. Diabetic Med 1995; 12: 717-722.
116. Clinical Standards Advisory Group. Access to and Availability of Coronary Artery Bypass Grafting and Coronary Angioplasty. London: HMSO, 1993.